Sequent Scientific Limited (SEQUENT.BO)
Sequent Scientific Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Mumbai, IN. The stock last traded at $202.40, down 0.78% on the session, giving a market capitalisation of $50.56B. Its beta of 0.96 implies it has historically moved less than the broad market.
Sequent Scientific Limited operates as a global entity primarily focused on the animal health industry. The company is engaged in developing and supplying active pharmaceutical ingredients (APIs) as well as formulated products tailored for various animal health applications. Its extensive product portfolio encompasses treatments for conditions such as internal and external parasitic infections (anthelmintics), protozoal diseases, nutritional supplementation (nutraceuticals), anti-inflammatory relief (nonsteroidal anti-inflammatory drugs), anti-infective agents, and dermatological remedies. Additionally, Sequent Scientific offers specialized analytical services to companies within the API, pharmaceutical, personal care, and nutraceutical sectors. These services include crucial method validation, stability testing, and microbiological analysis for both raw API materials and finished goods. Established in 1985, the company was previously known as PI Drugs and Pharmaceuticals Limited. Headquartered in Mumbai, India, Sequent Scientific operates as a subsidiary of CA Harbor Investments.
Sequent Scientific Limited is most often compared with the following Healthcare names: